Does Rallies show Form 4 insider transactions for FBIO?

Yes. Rallies tracks FBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is FBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FBIO. It does not provide personalized investment advice.

FBIO (Fortress Biotech, Inc.) Stock Analysis - Insider Trades

Fortress Biotech, Inc. (FBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, FBIO trades at $2.65 with a market cap of $82.38M and a P/E ratio of 0.69. FBIO moved +4.74% today. Year to date, FBIO is -37.94%; over the trailing twelve months it is +51.43%. Its 52-week range spans $1.33 to $4.53. Analyst consensus is buy with an average price target of $10.75. Rallies surfaces FBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading FBIO stock inside the company?

Recent FBIO insider activity includes ROSENWALD LINDSAY A MD bought 763.36K, ROSENWALD LINDSAY A MD bought 5.00K, Jin David bought 500, ROSENWALD LINDSAY A MD bought 5.00K, and ROSENWALD LINDSAY A MD bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

FBIO Key Metrics

Key financial metrics for FBIO
Metric	Value
Price	$2.65
Market Cap	$82.38M
P/E Ratio	0.69
EPS	$3.84
Dividend Yield	0.00%
52-Week High	$4.53
52-Week Low	$1.33
Volume	1.58K
Avg Volume	0
Revenue (TTM)	$66.16M
Net Income	$128.94M
Gross Margin	66.22%

Recent FBIO Insider Trades

ROSENWALD LINDSAY A MD bought 763.36K (~$1.40M) on Sep 23, 2024.
ROSENWALD LINDSAY A MD bought 5.00K (~$37.42K) on Jul 11, 2024.
Jin David bought 500 (~$3.75K) on Jul 10, 2024.
ROSENWALD LINDSAY A MD bought 5.00K (~$36.97K) on Jul 9, 2024.
ROSENWALD LINDSAY A MD bought 5.00K (~$36.76K) on Jul 8, 2024.

Latest FBIO News

Journey Medical Expands Emrosi Access to Over 150 Million Commercial Lives — Apr 21, 2026
Fortress Biotech Subsidiary Sells $205M PRV, Nets Over $100M — Mar 30, 2026
Fortress Biotech’s Cyprium Agrees to $205M Sale of FDA Priority Review Voucher — Feb 24, 2026
Cyprium to Sell Rare Disease Priority Review Voucher for $205 Million — Feb 23, 2026

FBIO Analyst Consensus

2 analysts cover FBIO: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.75.

Common questions about FBIO

Who is trading FBIO stock inside the company?: Recent FBIO insider activity includes ROSENWALD LINDSAY A MD bought 763.36K, ROSENWALD LINDSAY A MD bought 5.00K, Jin David bought 500, ROSENWALD LINDSAY A MD bought 5.00K, and ROSENWALD LINDSAY A MD bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for FBIO?: Yes. Rallies tracks FBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is FBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FBIO. It does not provide personalized investment advice.